MarketCap
Facebook
X
Telegram
Citius Pharmaceuticals EBITDA | CTXR
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Citius Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -38.5 M | -42 M | -36.7 M | -33.3 M | -23.5 M | -17.4 M | -15.6 M | -13.8 M | -9.98 M | -7.45 M | -3.23 M | - | -28.1 K | -19.6 K | -24.9 K | -15.5 K |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -15.5 K | -42 M | -16.1 M |
Quarterly EBITDA Citius Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.2 M | -9.02 M | - | - | - | - | - | - | - | - | -9.34 M | - | - | - | -7.25 M | -25.8 M | -8.92 M | -7.59 M | -9.26 M | -18.3 M | -5.98 M | -4.19 M | -8.16 M | -13.6 M | -4.69 M | -8.16 M | -4.45 M | -11.9 M | -4.43 M | -4.45 M | -3.87 M | -10.1 M | -2.02 M | -3.87 M | -3.24 M | -7.58 M | -2.25 M | -3.24 M | -2.78 M | - | -2.13 M | -2.78 M | -1.24 M | -2.26 M | -774 K | -1.24 M | -879 K | -550 K | -1.3 K | -879 K | -499 K | -13.4 K | -3.44 K | -298 | -636 | -15.1 K | -6.18 K | -636 | -2.2 K | -23.2 K | -7.1 K | -2.2 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -298 | -32.2 M | -5 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M |  USA |
 |
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
57 M | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
-82.7 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
19.5 B | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.75 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
-241 M | $ 0.36 | -10.07 % | $ 26.4 K | USA |
 |
Bio-Path Holdings
BPTH
|
-11.9 M | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-26.7 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
16.9 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-18.1 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-8.42 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-8.42 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-28.3 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-3.8 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-8.6 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
60.4 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
3.39 M | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-46.7 M | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
-45.2 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
17.3 M | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
40.2 M | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-118 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-211 M | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
-153 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-23.1 M | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
-2.54 M | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-12.6 M | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
481 M | $ 9.97 | -2.25 % | $ 1.62 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
-4.16 M | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-12.4 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
-119 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-111 M | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
-58.9 M | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
-58.2 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-5.11 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
-178 M | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
-8.44 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-13.7 M | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
-48.9 M | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
-17.8 M | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
-156 M | - | - | $ 1.2 B |  Australia |
 |
Verastem
VSTM
|
-170 M | $ 9.17 | 5.04 % | $ 636 M | USA |
|
BiomX
PHGE
|
-38.5 M | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
-38.6 M | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
-14.9 M | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
-24.4 M | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
-13.2 M | - | 5.59 % | $ 1.16 M | USA |